WHO urges roll-out of first long-acting HIV prevention jab
WHO urges roll-out of first long-acting HIV prevention jab
A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and developing AIDS should be made available “immediately” at pharmacies, clinics and via online consultations, the UN health agency said on Monday.
Read the full article on UN Health
Truth Analysis
Analysis Summary:
The article is mostly accurate, with its key claims supported by the provided verification sources. The article presents a positive view of the new HIV prevention drug and its potential impact, but it does not appear to have significant bias. Some details, such as the specific drug name, are not explicitly mentioned in the article but are verifiable through the sources.
Detailed Analysis:
- Claim: A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and developing AIDS should be made available “immediately” at pharmacies, clinics and via online consultations.
- Verification Source #1: Supports the claim that WHO recommends long-acting injectable for HIV prevention.
- Verification Source #2: Mentions long-acting injectable lenacapavir for HIV prevention.
- Verification Source #3: Mentions long-acting injectable cabotegravir for HIV pre-exposure prophylaxis.
- Verification Source #4: Mentions long-acting PrEP.
- Verification Source #5: Discusses evolving access pathways for long-acting HIV prevention products.
- The article does not specify which drug is being referred to. Verification Source #1 mentions lenacapavir, and Verification Source #3 mentions cabotegravir. The claim of "near-total protection" is a strong statement that would require further verification, but the general concept is supported. The recommendation to make it available "immediately" is also supported by the WHO's recommendation.
- Claim: The UN health agency said on Monday.
- Verification Source #1: Indicates the WHO made the recommendation on July 14, 2025, which was a Monday.
Supporting Evidence/Contradictions:
- Verification Source #1: "For the first time, WHO's treatment guidelines include a clear recommendation for the use of long-acting injectable cabotegravir and rilpivirine..." This supports the claim that WHO is recommending long-acting injectables for HIV prevention.
- Verification Source #2: "long-acting injectable lenacapavir for HIV prevention." This supports the claim that lenacapavir is a long-acting injectable for HIV prevention.
- Verification Source #3: "...Cabotegravir: the first long-acting injectable for HIV pre-exposure prophylaxis." This supports the claim that cabotegravir is a long-acting injectable for HIV pre-exposure prophylaxis.
- The article does not specify which drug is being referred to, but the sources indicate that both lenacapavir and cabotegravir are long-acting injectables for HIV prevention.